Advertisement

enGene Therapeutics Inc. ENGNW

Set alert

Price alert · ENGNW

All alert types
0.18 USD 0.00 0.00%

As of Oct 28, 1:18 PM ET

Bid
0.13 × —
Ask
0.21 × —
0.1813 Day range 0.1831
0.1813 52-week range 0.1813
YTD
0.00%
1 year
0.00%
Open
2.10
Prev close
0.1813
Mkt cap
9.28M
Vol
2.31K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
0.1813
High
0.1831
Forward P/E
0.00
Beta
-0.76
Short ratio
0.00
Inst. own
0.00%
Dividend
0.00
Ex-div date
50-d avg
0.00
200-d avg
0.00
1y target
0.00

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for ENGNW has not been loaded yet. Try again in a moment.

Key statistics

Market cap
0
Enterprise value
0
Trailing P/E
0.00
Forward P/E
0.00
PEG ratio
0.00
Price / sales
0.00
Price / book
0.19
EPS (TTM)
0.00
Beta
-0.76
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-23.58M
Total cash
257.68M
Total debt
24.86M
Return on equity
-123.06%
Shares outstanding
0
Short % of float
0.00%
50-day average
0.00
200-day average
0.00

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About enGene Therapeutics Inc.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.

Sector
Healthcare
Industry
Biotechnology
Country
Canada
Website
engene.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on ENGNW — it syncs with the Stock Master app.

Institution ownership

ENGNW institution ownership
Holder% heldSharesValueReported
Fcpm III Services B.v. 27.64%2,878,1482.79MSep 29, 2024
BVF Inc.9.08%945,402917.04KSep 29, 2024
Blue Owl Capital Holdings LP4.91%511,177495.84KSep 29, 2024
Omega Fund Management, Llc3.09%321,502311.86KSep 29, 2024
Saba Capital Management, L.P.1.85%192,334186.56KSep 29, 2024
Calamos Advisors LLC1.44%150,000145.50KSep 29, 2024

Fund ownership

ENGNW fund ownership
Holder% heldSharesValueReported
Saba Capital Income & Opportunities Fd0.06%6,0445.86KJul 30, 2024
Advertisement